Evaluering af effektiviteten af neothelium ft i behandlingen af kroniske åbne sår
Evaluering af effektiviteten af neothelium ft i helingen af kroniske åbne sår: et randomiseret kontrolleret multicenterforsøg
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Angelina Ferguson, DNP
- Telefonnummer: (985) 629-4013
- E-mail: info@sygnola.com
Undersøgelse Kontakt Backup
- Navn: Sarah Moore, MBE
- Telefonnummer: (985) 629-4013
- E-mail: info@sygnola.com
Studiesteder
-
-
Louisiana
-
Denham Springs, Louisiana, Forenede Stater, 70726
- Rekruttering
- MedCentris of Denham Springs
-
Ledende efterforsker:
- Monique Consoer, NP
-
Kontakt:
- Tabatha Yent
- E-mail: tabatha.yent@medcentris.com
-
Hammond, Louisiana, Forenede Stater, 70403
- Rekruttering
- MedCentris of Hammond
-
Ledende efterforsker:
- Chris Keaton, NP
-
Kontakt:
- Chelsea Smith, RN
- E-mail: Chelsea.smith@medcentris.com
-
Kontakt:
- Melanie Knox, LPN
- E-mail: Melanie.knox@medcentris.com
-
Lafayette, Louisiana, Forenede Stater, 70507
- Afsluttet
- MedCentris of Carencro
-
Leesville, Louisiana, Forenede Stater, 71146
- Rekruttering
- MedCentris of Leesville
-
Ledende efterforsker:
- Stefanie Corley, FNP
-
Kontakt:
- Brandi Shuff
- E-mail: Brandi.shuff@medcentris.com
-
Many, Louisiana, Forenede Stater, 71449
- Rekruttering
- MedCentris of Many
-
Ledende efterforsker:
- Stefanie Corley, FNP
-
Kontakt:
- Brandi Shuff
- E-mail: Brandi.Shuff@medcentris.com
-
Marksville, Louisiana, Forenede Stater, 71351
- Rekruttering
- MedCentris of Marksville
-
Ledende efterforsker:
- Averie Rachal, FNP
-
Kontakt:
- Laura Whittington
- E-mail: Laura.whittington@medcentris.com
-
Metairie, Louisiana, Forenede Stater, 70001
- Rekruttering
- MedCentris of Metairie
-
Kontakt:
- Ninya Powell
- E-mail: ninya.powell@medcentris.com
-
Ledende efterforsker:
- Sarah Logrande, NP
-
Minden, Louisiana, Forenede Stater, 71055
- Rekruttering
- MedCentris of Minden
-
Ledende efterforsker:
- Taheera Forbes, NP
-
Kontakt:
- Brianna Thompas
- E-mail: brianna.thompson@medcentris.com
-
Monroe, Louisiana, Forenede Stater, 71201
- Ikke rekrutterer endnu
- MedCentris of Monroe
-
Ledende efterforsker:
- Libbi Trawick, NP
-
Kontakt:
- Tiffany Dew
- E-mail: Tiffany.dew@medcentris.com
-
Slidell, Louisiana, Forenede Stater, 70458
- Rekruttering
- MedCentris of Slidell
-
Ledende efterforsker:
- Katie Schloegel, FNP
-
Kontakt:
- Donyille Singletary, RN
- Telefonnummer: 985-602-1215
- E-mail: Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville, Mississippi, Forenede Stater, 39540
- Afsluttet
- MedCentris of D'iberville
-
McComb, Mississippi, Forenede Stater, 39648
- Afsluttet
- MedCentris of McComb
-
Natchez, Mississippi, Forenede Stater, 39120
- Afsluttet
- MedCentris of Natchez
-
Southaven, Mississippi, Forenede Stater, 38671
- Rekruttering
- MedCentris of Southaven
-
Ledende efterforsker:
- Carlene McAllister, NP
-
Kontakt:
- De'Nyia Woods
- E-mail: denyia.woods@medcentris.com
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11234
- Rekruttering
- Northeast Podiatry Consultant
-
Kontakt:
- Thomas Hayes
- E-mail: thomas@simonfootandankle.com
-
Ledende efterforsker:
- David Simon, DPM, FACFAS
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
Eksperimentel: Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete Wound Closure
Tidsramme: 1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage Wound Area Change
Tidsramme: 1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
Tidsramme: Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Follow-Up Closure
Tidsramme: 2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
Tidsramme: Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
Tidsramme: 1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Studieleder: Angelina Ferguson, DNP, SygNola, LLC
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HEAL
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .